Stay updated with breaking news from Celcuity Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients
Celcuity Inc. (NASDAQ:CELC – Get Rating) has been assigned a consensus recommendation of “Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price […]
MINNEAPOLIS, MN / ACCESSWIRE / March 2, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients
Patients who received prior treatment with a CDK4/6 inhibitor > 2 prior therapies for ABC: 33% of patients ORR: 63% ... | December 10, 2021
78% ORR in 3rd line patients and 63% ORR overall in patients treated with three weeks on/one week off gedatolisib dosing schedule (Arm D)MINNEAPOLIS, MN / ACCESSWIRE / December 10, 2021 / Celcuity Inc.